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ABSTRACT
Objective: To assess the cost-effectiveness of lanthanum car-
bonate (LC) as a second-line therapy for hyperphosphatemia
in end-stage renal disease (ESRD) patients not achieving tar-
get phosphorus levels.
Methods: A cohort of ESRD patients not adequately main-
tained on calcium carbonate (CC) and three subgroups of
patients with baseline phosphorus levels of 5.6 to 6.5 mg/dl,
6.6 to 7.8 mg/dl, and more than 7.9 mg/dl were modeled.
The following policy options were considered: continued CC
(Policy 1); LC trial—if successful continue LC, if unsuccess-
ful switch to CC (Policy 2). The survival beneﬁt of using
second-line LC to improve phosphorus control has been
extrapolated from the relationship between hyperphos-
phatemia and mortality. Lifetime UK National Health
Service drug and monitoring costs, expected survival, and
quality-adjusted life-years (QALYs) were examined (dis-
counting at 3.5% per annum).
Results: Policy 2 had a cost-effectiveness ratio (cost/QALY)
of £25,033 relative to Policy 1. The results show it is partic-
ularly cost-effective to treat patients with phosphorus levels
above 6.6 mg/dl. The outcomes did not vary signiﬁcantly
during the one-way sensitivity analysis carried out on
important model parameters and assumptions except when
the utility value for ESRD was decreased by more than
30%.
Conclusions: Applying a cost-effectiveness threshold of
£30,000 per QALY, the model shows it is cost-effective to
follow current treatment guidelines and treat all patients who
are not adequately maintained on CC (serum phosphorus
above 5.6 mg/dl) with second-line LC. This is particularly the
case for patients with serum phosphorus above 6.6 mg/dl.
Our estimates are probably conservative as the possible com-
pliance difference  in  favor  of  LC  and  the  reduced  number
of hypercalcemic events with LC relative to CC was not
considered.
Keywords: calcium carbonate, cost-effectiveness, end-stage
renal disease, hyperphosphatemia, lanthanum carbonate,
phosphorus.
Introduction
End-stage renal disease (ESRD) is the terminal stage of
chronic kidney disease. It affects one million individu-
als worldwide [1], and the prevalence is increasing by
around 7% per annum because the growing elderly
population and the rising incidences of diabetes melli-
tus and hypertension [2,3]. Current treatment involves
renal replacement therapy, ideally by transplant, but
until that point by renal hemodialysis. Life expectancy
on dialysis is typically less than 10 years [4].
Hemodialysis fails to clear excess phosphorus from
the body in the majority of hemodialysis patients,
resulting in hyperphosphatemia, which is associated
with increased morbidity, including hyperparathy-
roidism and renal osteodystrophy [5]. Phosphorus
metabolism is also dynamically linked with that of cal-
cium, with bone acting as the main reservoir for both
minerals. Increases in serum phosphorus lead to stim-
ulation of parathyroid hormone and a consequent
mobilization of calcium from bone and decrease in
renal calcium excretion.
A study by Block et al. [5] showed that serum phos-
phorus levels above 5.5 mg/dl are also associated with
a signiﬁcantly increased relative risk (RR) of mortality.
A recent update conﬁrmed this association [6] and
showed that increased levels of serum calcium (i.e.,
hypercalcemia) are also linked to a raised mortality
risk. An increased mortality risk is also associated with
calcium × phosphorus (Ca × P) product [5,7].
Treatment guidelines issued by the Kidney Disease
Outcomes Quality Initiative (K/DOQI) of the US
National Kidney Foundation recommend that serum
phosphorus levels should be maintained between 3.5
and 5.5 mg/dl [8]. The guidelines further recommend
that serum calcium should be maintained at the lower
end of the normal range (8.4–9.5 mg/dl). Ca × P prod-
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uct should be monitored and maintained below
55 mg2/dl2. Evidence suggests that many patients do
not currently meet these targets. A US study of 4000
patients showed that only 44% of patients achieve the
K/DOQI target for serum phosphorus [9].
Current treatment of hyperphosphatemia involves
a combination of dietary restrictions and the use of
phosphate binders. These agents, taken with or shortly
after food, bind with phosphate in the gastrointestinal
tract, preventing its absorption into the blood. The
most commonly used phosphate binders are calcium
salts. In Europe, standard treatment is calcium carbon-
ate (CC) and in the United States, calcium acetate is
more commonly used. Calcium salts are relatively
inexpensive and have been the standard therapy for
almost 20 years (because the toxic effects of aluminum
salts became widely known [10]). For a large propor-
tion of patients, calcium salts are effective in achieving
target serum phosphorus levels. Nevertheless, when
calcium agents are ineffective, a common response is to
increase their dose, which can result in hypercalcemia
[11]. The K/DOQI guidelines now recommend that
patients’ total intake of calcium (from diet and drug
treatment) should not exceed 2000 mg/day [8]. This
means that, in some patients, clinicians cannot simul-
taneously minimize the risks of mortality and hyper-
calcemia and there is a clinical need for alternative
phosphate binders.
Our study examines the cost-effectiveness of lantha-
num carbonate (LC), a new, noncalcium, nonalumi-
num phosphate binder. Randomized, controlled trials
(RCTs) of LC have shown clinically effective reduction
of serum phosphorus levels for patients with ESRD
[12–15]. The trials reveal no increase in calcium levels
and a reduced incidence of hypercalcemia, compared
with CC [13,16]. LC therefore provides an alternative
treatment for patients who are not adequately control-
led on CC. Because LC will have higher unit costs
than CC, the question arises whether the health gains
offered are worthwhile. Recent North American writ-
ing [17] recommends detailed analysis on the expected
costs and beneﬁts of phosphate binding agents. Our
study aims to assess the expected cost-effectiveness of
LC as a second-line therapy for hyperphosphatemia in
ESRD patients who fail to achieve target phosphorus
levels on standard, calcium-based therapy. The analy-
sis has been carried out from a UK NHS perspective.
Costs considered have been restricted to the direct
costs of phosphate binders. Differences in other costs
are unlikely to be important in this case.
Methods
Efﬁcacy Evidence
Data on the efﬁcacy of LC in ESRD patients with
hyperphosphatemia come from the Phase III study by
Hutchison et al., which compared the efﬁcacy of LC
(n = 510) with that of CC (n = 257) over 6 months
(RCT phase) [13]. Study end points were serum phos-
phorus and Ca × P product levels. Patients were
included if, after 1 to 3 weeks of washout, their serum
phosphorus levels exceeded 5.58 mg/dl (LC: n = 277,
CC: n = 152). A 6-month open-label extension was
also undertaken, in which all patients received LC.
This enabled longer-term follow-up of patients on LC,
as well as providing further data on 181 patients ini-
tially randomized to CC who switched to open-label
LC. Many of the data inputs for our cost-effectiveness
model were derived using patient level data from this
study.
Model Overview
This  cost-effectiveness  analysis  is  based  on  a  model
of clinical pathways (Fig. 1). The following policy
options for the treatment of ESRD patients with hyper-
phosphatemia who are not adequately maintained on
CC were examined: continued treatment with CC (Pol-
icy 1); an 8-week LC trial period; if successful, then LC
continuation; if unsuccessful, then switch back to
maintenance on CC (Policy 2). Patients who are ini-
tially successful on LC but who become unsuccessful
after long-term use of LC are also switched back to
CC. The rationale for switching unsuccessful patients
back to CC is that LC should only be used when it
achieves a better response than CC because it is more
expensive. These two policy options were developed
Figure 1 Pathways model diagram. Patient numbers and relative risks (RR) of mortality are shown for the base case. CC, calcium carbonate; LC, lan-
thanum carbonate.
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after discussion with clinicians regarding the appropri-
ate clinical pathway for using LC as a second-line
treatment for hyperphosphatemia. Although the two
policies do not differ for patients who are adequately
maintained on CC these patients are included in the
model because they are relevant to the overall costs of
each policy.
Clinicians might allow patients to have repeated tri-
als on LC, either sometime after an initial failed trial
period on LC or sometime after returning to CC ther-
apy after a period of nonresponse to long-term LC.
There is an absence of evidence on the probability of
succeeding on LC during such a subsequent trial. We
have undertaken a sensitivity analysis by making a
series of assumptions, which are unfavorable to the LC
policy as follows: 1) drug and monitoring cost for any
subsequent trial period on LC is included (undis-
counted); 2) there is zero probability of response on
each of the subsequent trials; and 3) both those who
fail the initial trial period and those who succeed in
responding for a time receive subsequent trial periods.
Effectively, we include all of the costs but assume zero
beneﬁt, to be as unfavorable as possible and to avoid
making any assumption on this probability in the
absence of evidence.
The pathways model was evaluated twice using dif-
ferent deﬁnitions of successful response: ﬁrst, phos-
phorus level below 5.6 mg/dl, and second, a Ca × P
product value below 53 mg2/dl2. These thresholds
reﬂect the cut levels found by Block et al. [5] for an
increased mortality risk and are also close to the upper
thresholds of the K/DOQI guidelines.
Patient Population Characteristics
A cohort of 1000 patients with ESRD was modeled
(Fig. 1). We also analyzed three subgroups, that is,
patients with baseline phosphorus levels of 5.6 to
6.5 mg/dl (Block group 3), 6.6 to 7.8 mg/dl (Block
group 4), or above 7.9 mg/dl (Block group 5).
Probability Estimates for Clinical Outcomes
The numbers of patients responding, withdrawing, etc.
were estimated using patient level data from the trial
by Hutchison et al. [13]. The proportion of patients on
CC who successfully achieve target levels was stable
over time (Fig. 2), the average being 70% for the phos-
phorus target and 62% for Ca × P product. In the
phosphorus target model, we therefore assumed that
70% of patients are successful on ﬁrst-line CC and
30% are eligible for a trial period on second-line LC.
This is close to the Canadian reported 35% of patients
taking calcium based phosphate binders who had
serum phosphorus levels of more than 5.5 mg/dl [17].
We used patient level data from Hutchison et al.
[13] to estimate the proportion of patients who suc-
cessfully respond to LC by calculating the probability
of a patient moving from one phosphorus subgroup to
another after starting treatment with LC. In the base
case we considered patients starting treatment with LC
at the beginning of the trial, most of whom where on
CC before the trial, and used the average transition
from the start of the trial to all subsequent visits. This
gave a probability of successful response to LC of
62%. As an alternative estimate we considered the
average transition for patients who switched from CC
to LC at the start of the open-label phase, which gave
an estimate of 52%. When repeating these two esti-
mates for the Ca × P product target we obtained esti-
mates of  61%  and  49%,  respectively.  The  impact
of using these alternative estimates was examined
through a sensitivity analysis.
Not all patients maintain their response over the
longer term. We analyzed patient level data from
Hutchison et al. [13] and the open-label extension of
that study to calculate the duration of successful
response to LC. Patients were included in the analysis
(N = 210) if they had shown a successful response to
LC over a 9-week period which is similar to the 8-week
trial modeled. In our analysis, patients who did not
achieve the target level on two consecutive visits were
deemed not successfully maintained, and those who
were lost to follow-up were treated as censored. The
duration of successful maintenance of effect on LC
was analyzed using the Kaplan–Meier approach and
extrapolated into the long-term by ﬁtting a Weibull
model to the data (Fig. 3).
Figure 2 Proportion of patients on calcium
carbonate who achieve the phosphorus target
(less than 5.6 mg/dl) during trial by Hutchison
et al. [13].
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Survival Evidence
To calculate survival, it was assumed that patients
have an RR of mortality corresponding to their phos-
phorus level, as described by Block et al. [5] (Table 1).
Patients who return to CC after a period on LC were
assumed to return to the phosphorus (or Ca × P prod-
uct) level they had previously achieved on CC and
therefore to their previous RR of mortality. In the
base-case model, we used all of the RR estimates pre-
sented by Block et al. including the nonsigniﬁcantly
increased RR for the group with a phosphorus level of
5.6 to 6.5 mg/dl.
These RRs were applied to a baseline expected sur-
vival curve for ESRD patients. The best evidence on
long-term survival has been provided by the US Renal
Data System (USRDS) [18]. It is based on 10 years’ fol-
low-up of 43,000 incident dialysis patients (this was
preferred to UK Renal Registry data [19], which are
based on follow-up only for 5 years). Figure 4 shows
Figure 3 Proportion of patients initially responding to lanthanum car-
bonate who are successfully maintained in the long term.
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Table 1 Model inputs
Parameter Value Data source
Successful response to CC 70% for phosphorus target
62% for Ca × P product target
Patient level data from 
Hutchison study [13]
Successful response to 
LC after an 8-week trial
62% Patient level data from 
Hutchison study* [13]
Long-term successful 
response to LC
Weibull survival function
S(t) = exp{–λtγ}
λ = 0.57 and γ = 0.92
Patient level data from 
Hutchison study [13]
Survival Weibull survival function
S(t) = exp{–λtγ}
λ = 0.23 and γ = 0.97
USRDS [3]
RR of survival associated 
with phosphorus range
1.1–4.5 mg/dl: 1.00
4.6–5.5 mg/dl: 1.00
Block et al. [5]
5.6–6.5 mg/dl: 1.02
6.6–7.8 mg/dl: 1.18
7.9–16.9 mg/dl: 1.39
RR of survival associated 
with Ca × P product range
14–42 mg2/dl2: 1.06
43–52 mg2/dl2: 1.00
Block et al. [5]
53–60 mg2/dl2: 1.08
61–72 mg2/dl2: 1.13
73–132 mg2/dl2: 1.34
Utility of ESRD 0.6 [21–26]
Utility of vomiting 0.27 [29]
Duration of AE (vomiting) 7 days [28]
Annual cost of CC (£) 400 BNF
Annual cost of LC (£) 1983 Average dose from Hutchison
et al. [13] and price per unit 
from Price Alert (Medi-Span)
Discounting 3.5% for costs and beneﬁts NICE reference case
*Based on phosphorus levels from comparator controlled phase [13].
AE, adverse event; BNF, British National Formulary; CC, calcium carbonate; ESRD, end-stage renal disease; LC, lanthanum carbonate; RR, relative risk; USRDS, US Renal Data
System.
Figure 4 Survival curve for US Renal Data System (USRDS) incident dial-
ysis patients and implied survival curves for patients in different Block
groups who have failed to achieve the target on calcium carbonate or lan-
thanum carbonate.
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our longer-term extrapolation of the USRDS survival
data, again ﬁtting a Weibull model. This was adjusted
to account for the phosphorus levels of USRDS
patients [5] to give a baseline survival for patients
without an increased risk of mortality due to raised
phosphorus levels (serum phosphorus of less than
5.6 mg/dl). From this baseline, we calculated the
implied survival curve for patients with higher phos-
phorus levels (Fig. 4).
Quality of Life Evidence
Total life-years were calculated and converted to qual-
ity-adjusted life-years (QALYs) using published utility
estimates for ESRD patients. A review of quality-of-life
literature and the Harvard Catalog of Preference
Scores [20] revealed seven published quality-of-life
studies for renal failure and seven for dialysis patients.
These gave health utilities ranging from 0.41 for dial-
ysis [21] to 0.826 for renal failure [22]. More speciﬁ-
cally, four studies involving ESRD patients [22–25]
and one involving patients with chronic renal failure
[26] estimated utilities in the range of 0.567 to 0.61.
We decided to use a utility of 0.6 in the base-case
model.
In the Hutchison study [13] several adverse events
were reported with higher frequency in the LC arm
although vomiting was the only adverse event whose
occurrence was signiﬁcantly higher (at P = 0.05) in the
LC arm. Using the adverse event frequencies reported
by Hutchison et al. [13] we estimated that vomiting is
7% more common in patients receiving LC compared
with those receiving CC. An analysis carried out by the
US Food and Drug Administration on a second rand-
omized controlled study of LC versus standard therapy
showed that vomiting was 5% more common in the
LC arm compared with the alternative therapy arm
[27]. An analysis of the duration of vomiting in this
second study carried out by Shire Pharmaceuticals
Group plc showed that the average duration of vom-
iting in the LC arm was between 6 and 8 days with
82% of episodes lasting less than 7 days [28]. In the
base case we assumed that patients who reported expe-
riencing vomiting did so for an average of 7 days at the
start of their treatment with LC. Alternative durations
were considered in a sensitivity analysis. We assumed a
utility of 0.27 for vomiting, which was derived from a
visual analog score provided by patients after chemo-
therapy who were asked to score the quality of life for
chemotherapy with and without nausea/vomiting [29].
Hypercalcemic events were more common in the CC
arm of Hutchison et al. [13] but the impact of these
events have been excluded from this analysis because a
lack of evidence of their impact on quality of life.
Costs
All costs were estimated from the perspective of the
UK National Health Service (NHS). Only direct costs
for medications were considered. It is unlikely that
other costs would differ signiﬁcantly except to the
extent those higher costs might occur directly in asso-
ciation with higher mortality in a group experiencing
higher phosphorus levels. We have chosen not to con-
cern ourselves that a few patients who would have died
are expected to live to incur other costs in the future. It
would be perverse to recommend not saving someone
from early death on the grounds that they could then
go on to incur costs from treatments that might them-
selves be regarded as not cost-effective. That logic
could lead to the rejection of an effective treatment
even if it were free.
Patients in the Hutchison study [13] used 1500 mg
to 9000 mg of CC per day. British National Formulary
data were used to estimate the annual cost of providing
these doses with either Adcal-D3® (ProStrakan,
Galashiels, U.K.) or Calcium-500® (Martindale,
Brentwo, U.K.). This resulted in annual estimates of
£68.44 and £111.36, respectively, for a low dose, and
£410.63 and £668.17, respectively, for a high dose.
Typical annual costs of Calcichew (Shire Pharmaceu-
ticals, Basingstake, U.K.) are estimated at around
£200. We used an estimated annual cost for CC of
£400 in our model and explored the sensitivity of our
results to this assumption.
At the time of analysis, there had been no formal
decision on the price of LC in the UK. We have taken
the US average wholesale price for LC of $2.2 per
500 mg tablet (Price Alert, Medi-Span), and converted
this to a UK price using purchasing power parity rates
(1£ = 0.64$ [30]). We have then used the average daily
dose of LC from Hutchison et al. [13] to calculate an
annual cost for LC of £1983. The cost of the 8-week
trial period on LC was calculated pro rata at around
£305. Using the most frequently administered dose
from the Hutchison study [13] rather than the average
dose gave an annual cost of £1542 while personal
communications with Shire Pharmaceuticals Group
plc have suggested that the annual price may be close
to £1800. These two alternative prices have been
examined in a sensitivity analysis.
Because the analysis is performed using the speciﬁ-
cations of the National Institute for Clinical Excellence
(NICE) in the UK, all costs and beneﬁts are discounted
at 3.5%.
One-way sensitivity analyses were carried out to
determine the impact of changing the key uncertain
variables and assumptions (Table 2).
Structural Sensitivity Analysis
The base-case model aggregates patients with different
phosphorus levels into one group, for which we calcu-
lated a mean RR of mortality. Nevertheless, this is an
approximation that assumes that the proportion of
patients per Block group does not change over time
within each branch of the model. In fact, because
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patients with higher phosphorus levels have a higher
RR of mortality, their number will decline over time.
We assessed in a structural sensitivity analysis whether
this simpliﬁcation materially affects the overall results
of the base-case analysis. For this purpose, the results
for each Block group were aggregated according to the
proportion of patients in each Block group in the start-
ing cohort.
Results
Base-Case Analysis
The estimated costs and beneﬁts of the two clinical
pathways for a population of patients with ESRD are
shown in Table 3. The analysis reveals that a strategy
of second-line LC treatment (Policy 2) is cost-effective
when compared with CC therapy (Policy 1) over a life-
time horizon. Under Policy 2, we estimate 188 success-
ful responders to LC who continue long-term on this
treatment (Fig. 1). On the cost side, the additional
drug costs of £1583 per patient on LC per annum
translate into a lifetime cost difference for the cohort
of £443,000. Most of the incremental cost is incurred
in the ﬁrst 2 years (Table 3), and costs decrease as
patients stop LC therapy and are returned to CC (less
than 1% of the cohort is receiving LC at 5 years).
Nevertheless, beneﬁts are still being accrued because
patients whose phosphorus levels have been controlled
up to that point are more likely to have survived. More
patients achieve their target phosphorus levels (by Year
one, 654 patients under Policy 2 achieve the target
phosphorus level, compared with 563 patients under
Policy 1), thus reducing the estimated mortality risk of
the cohort. The model estimates 369 patients alive at
5 years under Policy 1 and 372 under Policy 2. This
produces an estimated 39 (undiscounted) life-years
gained for the 1000 patients over their expected life-
time, which equates to 18 QALYs (discounted). The
estimated lifetime cost-effectiveness ratio for the
cohort is £25,033 per QALY gained. If shorter time
horizons are examined, then the use of LC is not cost-
effective when ignoring beneﬁts beyond 5 or 10 years.
The subgroup analysis in Table 4 shows substantial
variation of outcomes between the Block groups
particularly in terms of beneﬁts. For patients with
phosphorus  levels  above  7.9 mg/dl,  second-line  LC
is expected to provide an additional 150 QALYs, rela-
tive to CC, whereas patients with less severe hyper-
phosphatemia (phosphorus levels of 5.6–6.5 mg/dl)
have an estimated gain of just 12 QALYs. The cost-
effectiveness ratios are clearly favorable for patients
with phosphorus levels above 6.6 mg/dl, but less so
for the subgroup with phosphorus levels of 5.6 to
6.5 mg/dl.
Table 2 Summary of the sensitivity analysis carried out on the major assumptions and evidence used in the model
Parameter Base case Sensitivity analysis
Length of trial period on LC 8 weeks 1 week
Duration of AE (vomiting) 7 days 1 day, 1 month
Discounting for costs and beneﬁts 3.5% for both 0% for both, 6% for both
RR of mortality [5] Nonsigniﬁcant* Signiﬁcant†
Utility of ESRD 0.6 0.41 [21], 0.826 [22]
Annual cost of LC (£) 1983 1542, 1800
Annual cost of CC (£) 400 68.44, 668.17
Efﬁcacy of LC in patients who are
not adequately maintained on CC
62%‡ 52%§, 49%||, 61%¶
*Include patients with no signiﬁcant increase in mortality risk.
†Include patients with a signiﬁcantly increased mortality risk only.
‡Based on phosphorus levels from comparator controlled phase [13].
§Based on phosphorus levels from open-label phase [13].
||Calcium phosphorus levels from open-label phase [13].
¶Calcium phosphorus levels from comparator controlled phase [13].
AE, adverse event; CC, calcium carbonate; ESRD, end-stage renal disease; LC, lanthanum carbonate; RR, relative risk.
Table 3 Base-case results for 1000 patients
Policy 1
(CC for all)
Policy 2 
(second-line LC) Policy 2 vs. 1
Cost (£ thousand)
Lifetime 1720 2164 443
2 years 635 976 341
5 years 1170 1596 426
10 years 1540 1981 441
Life-years gained
Lifetime 4301 4331 30
2 years 1587 1592 6
5 years 2924 2940 16
10 years 3850 3874 24
QALYs gained
Lifetime 2581 2598 18
2 years 952 955 3
5 years 1754 1764 9
10 years 2310 2324 14
Cost per life-year gained (£)
Lifetime 14,906
2 years 60,771
5 years 26,847
10 years 18,434
Cost per QALY gained (£)
Lifetime 25,033
2 years 105,521
5 years 45,389
10 years 31,015
CC, calcium carbonate; LC, lanthanum carbonate; QALY, quality-adjusted life-year.
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Sensitivity Analysis
The results of the one-way sensitivity analyses exam-
ining the effect of changing the key uncertain variables
and assumptions on the cost-effectiveness of second-
line LC versus continued CC for the cohort of ESRD
patients is shown in Figure 5.
Structural Sensitivity Analysis
For second-line LC, the aggregated (base-case) model
predicts incremental costs versus CC alone of
£443,000, as does the nonaggregated estimate. Incre-
mental QALYs are slightly different, with 17.7 QALYs
for the aggregated model versus 16.1 QALYs for the
nonaggregated estimate, resulting in an increase of
10% in the cost per QALY if the nonaggregated model
is used.
Discussion
Although there is some existing evidence on the cost-
effectiveness of other noncalcium phosphate binders
[17,31], this is the ﬁrst study to examine the potential
cost-effectiveness of using LC in the treatment of
hyperphosphatemia. Our model assesses the costs and
beneﬁts of using LC to lower phosphorus levels in
patients whose levels are still uncontrolled after treat-
ment with standard therapy (CC). The results are
driven by the increased mortality risk for patients with
uncontrolled phosphorus levels. The results show that
there is a beneﬁt in using second-line LC and that the
beneﬁts are larger for patients with higher phosphorus
levels. The cost-effectiveness ratios for a cohort of
1000 patients with the starting phosphorus levels seen
in the pivotal LC trial by Hutchison et al. [13] are
Table 4 Base-case subgroup results (1000 patients, lifetime horizon)
Policy 1 (CC for all) Policy 2 (second-line LC) Policy 2 vs. 1
Patients with phosphorus levels >7.9 mg/dl (Block group 5)
Cost (£ thousand) 1282 2625 1,343
QALYs gained 1922 2073 150
Cost per QALY gained (£) 8,935
Patients with phosphorus levels of 6.6–7.8 mg/dl (Block group 4)
Cost (£ thousand) 1514 2955 1,442
QALYs gained 2270 2361 91
Cost per QALY gained (£) 15,865
Patients with phosphorus levels of 5.6–6.5 mg/dl (Block group 3)
Cost (£ thousand) 1744 3222 1,478
QALYs gained 2616 2628 12
Cost per QALY gained (£) 123,831
CC, calcium carbonate; LC, lanthanum carbonate; QALY, quality-adjusted life-year.
Figure 5 Sensitivity and subgroup analysis on the cost-effectiveness of Policy 2 versus Policy 1. *Include patients with a signiﬁcantly increased mortality
risk only. LC, lanthanum carbonate; QALY, quality-adjusted life-year; Source P2, Phosphorus levels from open-label phase; Source CP1,
calcium × phosphorus product levels from open-label phase; Source CP2, calcium × phosphorus product levels from comparator controlled phase.
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below £30,000, relative to CC. Subgroup analysis
shows better cost-effectiveness for patients with phos-
phorus levels above 6.6 mg/dl because the increased
risk of mortality. The implication of this analysis is
that the mortality risk associated with raised phos-
phorus levels makes it cost-effective to control phos-
phorus using a more expensive phosphate binder when
a cheaper phosphate binder has failed to provide
control.
Overall the one-way sensitivity analysis showed
that second-line LC is still cost-effective when most
of the uncertain model parameter values are changed.
The model is not sensitive to changes in the length of
the trial period on LC (decreasing the length of the
trial period from 8 weeks to 1 week changed the cost
per QALY by less than 10%). Importantly, the model
was not sensitive to changes in the data source used
to estimate the efﬁcacy of LC in patients who are not
adequately maintained on CC. Using only the statisti-
cally signiﬁcantly increased mortality risk from Block
et al. [5], rather than including the nonsigniﬁcantly
increased RR for the group with a phosphorus level
of 5.6 to 6.5 mg/dl, increased the cost-effectiveness
ratio in the overall group to £30,406 putting it just
above the threshold. The model is sensitive to sig-
niﬁcant changes in the utility estimate for ESRD.
Decreasing utility to the lowest value found in the
Harvard Catalog of Preference Scores (0.41) increased
the corresponding cost per QALY to £36,527.
Changing  the  assumed  duration  of  vomiting  for
each reported incidence of vomiting from 7 days to
1 month did not impact signiﬁcantly on the cost-
effectiveness. The model is fairly sensitive to the value
used for the cost of LC as using the lower price of
£1542 per annum, which relates to the most com-
monly used dose, reduced the cost per QALY to less
than £20,000. Similarly the model is fairly sensitive to
the value used for the annual cost of CC with the
lower price of £68.44 giving a cost per QALY of
£29,578 and the higher price of £668.17 giving a cost
per QALY of £21,356. Changing the discount rates
caused a 20% change in cost per QALY in either
direction suggesting that the model is sensitive to the
timing of the costs and beneﬁts. Allowing patients to
receive additional unsuccessful trial periods on LC
increased the costs of second-line LC for the whole
cohort, giving cost per QALY results of £26,600,
£28,200, and £29,800 for one, two, and three addi-
tional unsuccessful trials, respectively. For patients
with phosphorus levels above 6.6 mg/dl, the cost per
QALY is still less than £30,000 even when the costs
of seven subsequent unsuccessful trial periods are
included. Finally, the results of the structural sensitiv-
ity analysis concerning the aggregation of patients in
the overall cohort of the base-case model show that
this simpliﬁcation does not materially affect the
results.
Our model is based on evidence provided by Block
et al. [5] that high phosphorus levels are associated
with an increased RR of mortality. Since we devel-
oped this model, Block and colleagues have published
further evidence to support this association [6]. Block
et al. also found that higher calcium levels are asso-
ciated with a signiﬁcantly increased mortality risk,
even among patients whose phosphorus levels are
within the K/DOQI guideline range. These events are
generally managed through dose changes, but in
some cases, they can lead to hospitalization. Clinical
evidence shows that the number of hypercalcemic
events is signiﬁcantly reduced in patients receiving
LC, compared with those receiving CC [13,16]. Nev-
ertheless, the cost impact of hypercalcemic events
was excluded from our present analysis because there
are no quantiﬁed data on either the resource
consequences or the utility impact of these events.
This exclusion may bias the results in favor of the
comparator.
We have chosen not to consider the increased
resource use associated with an increased survival rate
in our analysis. The inclusion or exclusion of these
costs in health economic evaluations is a point of
debate. This study is a prime example of the rationale
for excluding such costs. Hemodialysis is an expen-
sive treatment. Winkelmayer et al. [32] carried out a
review of the international literature for economic
evaluations of renal replacement therapy, which
included two UK studies [33,34], and found typical
cost per life-year for hospital dialysis in excess of
US$60,000 (cost per QALY of $100,000 when apply-
ing a utility of 0.6), which is substantially higher than
typical NICE thresholds (cost per QALY of £30,000).
Therefore, any additional treatment that incurs costs
while increasing survival will also have a cost per
QALY substantially above threshold if hemodialysis
costs are included. Ironically therefore an intervention
would actually have to shorten life expectancy rather
than save lives to achieve a cost per QALY below the
NICE threshold. The argument against including
hemodialysis costs is that policymakers have already
decided that this intervention is worthwhile and
should be provided.
In the absence of published quantiﬁed data relating
higher phosphorus levels to increased resource use, we
have excluded this issue from our analysis as well. We
have also excluded the cost of monitoring phosphorus
levels. This is part of the routine monitoring of dialysis
patients, and we have therefore assumed that the asso-
ciated costs are equivalent in all arms of the model.
The costs of death due to renal failure have not been
included in this analysis. The impact of this omission is
expected to be small because the model takes a lifetime
perspective in which all modeled patients die at some
point in the model. Therefore, the only difference in
the costs of death would be due to the effect of delay-
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ing death and therefore incurring a lower cost because
higher discounting.
It has been possible to consider the costs of repeated
trial periods on LC but not the beneﬁts because there is
an absence of evidence on the probability of success
during subsequent trial periods. The sensitivity analy-
sis shows that even if several subsequent unsuccessful
trial periods occur, the costs do not increase sufﬁciently
to change the conclusion regarding cost-effectiveness
of offering second-line LC. Further research is needed
on the probability of success in subsequent trials
before a detailed protocol on the optimum number of
trial periods can be devised.
This study has other limitations; there is potential
for improved compliance with LC, compared with CC,
because LC is a one-tablet-per-meal therapy, whereas
treatment with CC can require patients to take 9 to 12
tablets daily. Nevertheless, there is no quantiﬁed evi-
dence of compliance rates for these treatments in prac-
tice. We have therefore not considered the cost or
QALY differences due to this issue.
Our study has several implications for future
research. Longer-term observational studies of the
impact of using LC as a second-line therapy, both on
phosphorus control and the potential associated sur-
vival beneﬁt, would provide useful further validation.
It could also be beneﬁcial to have more evidence on
resource use, including resources associated with
hypercalcemic events, and whether resource use is
reduced in patients whose phosphorus levels are well
controlled because a reduced need for monitoring.
Analysis of ﬁrst-line use of LC could also be under-
taken (overall  or  in  some  patients  groups)  taking
into account the recently published evidence on the
increased risks associated with high metabolic levels of
calcium. Furthermore, it may be possible to adapt the
model to consider calcium acetate or sevelamer, rather
than CC, as the comparator. Finally, we have restricted
ourselves to a UK NHS perspective, but it will be pos-
sible to adapt the model for use in other countries.
The budget implications of making LC available in
the UK as a second-line therapy are substantial because
the high costs of dialysis. According to the UK renal
registry there are 37,000 patients receiving renal
replacement therapy in the UK with 39% of these
receiving hemodialysis. The proportion of these
patients achieving the target phosphorus level is simi-
lar to that modeled (60%), leaving an estimated 5778
patients eligible to receive second-line LC [19]. The
additional cost of making second-line LC available for
all patients who are not currently achieving the phos-
phorus target on CC would be £26.2m, with £8.2m
relating to the direct costs of providing LC and the
rest relating to the increased requirement for dialysis
because improved survival (These cost estimates
assume an annual cost for hemodialysis of £22,000)
[35]. If we assume that a third of the patients not
achieving the target fall into each of the subgroups
considered in this analysis, then making second-line
LC available to only those in the two most cost-
effective subgroups (those with phosphorus levels
above 6.6 mg/dl) would decrease the overall cost to
£22.4m with only £5.4m related to the direct costs of
providing second-line LC.
In conclusion, this study has used the evidence cur-
rently available to assess the cost-effectiveness of LC as
a second-line therapy for hyperphosphatemia in ESRD
patients. Applying a cost-effectiveness threshold of
£30,000 per QALY, the model suggests that it will be
cost-effective to follow K/DOQI guidelines and treat
all patients who are not adequately maintained on CC
(phosphorus level above 5.6 mg/dl) with second-line
LC. When individual subgroups are considered, the
results show that it is particularly cost-effective to treat
patients with phosphorus levels above 6.6 mg/dl and
that providing second-line LC to only these patients
would represent the most efﬁcient use of resources.
Source of ﬁnancial support: This study was funded by Shire
Pharmaceuticals Group plc.
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